Summary: Aerie has 2 marketed products and decent pipeline after a recent acquisition. Aerie unfortunately
Summary: Today, we revisit ocular concern Aerie Pharmaceuticals. The company has struggled as a newly
Summary: Sell-side estimates for this quarter’s revenue are too high and have begun to be
Summary: We revisit Aerie Pharmaceuticals. The stock has had a wild ride, getting crushed in the
Summary: Aerie Pharmaceuticals was one of my two favorite shorts as recently as August 2018.